Thoracic Paravertebral Block for Postoperative Pain Management After VATS

King Hussein Cancer Center

Status: Completed

Conditions: Pain, Postoperative

Treatments: Drug: 0.4 ml/kg of 0.5% bupivacaine

Study type: Interventional

Funder types: Other

Identifiers

NCT06689358

22 KHCC 158

Details and patient eligibility

About

This randomized controlled trial evaluated the efficacy of a thoracic paravertebral block (TPVB) in reducing opioid requirements and pain intensity in the PACU after video-assisted thoracoscopic surgery (VATS).

Full description

This randomized controlled trial evaluated the efficacy of a thoracic paravertebral block (TPVB) in reducing opioid requirements and pain intensity in the PACU after video-assisted thoracoscopic surgery (VATS). Adult patients scheduled for elective VATS who meet the eligibility criteria will be randomized to either Arm:

Arm 1: General anesthesia with TPVB;

Arm 2: General anesthesia alone (control group).

Primary Outcome: to assess Opioid requirement in the PACU

Enrollment: 81 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients scheduled for elective VATS, ASA physical status II-III, BMI 19-40.

Exclusion criteria

• Patient refusal, coagulation disorders, contraindications to TPVB, chronic analgesic use, mental illness

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

81 participants in 2 patient groups

General anesthesia with TPVB

Experimental group

Description:

0.4 ml/kg of 0.5% bupivacaine injected into the thoracic paravertebral space

Treatment:

Drug: 0.4 ml/kg of 0.5% bupivacaine

General anesthesia alone (control group).

No Intervention group

Description:

General anesthesia SOC alone